All News
#EULAR2022 POS0199 showed marked decrease in SARS-CoV2 IgG ab 6 months after initial two dose vaccines. @RheumNow https://t.co/lZdWQUqFvf
Dr. Rachel Tate uptoTate ( View Tweet)
Are JAKi fulfilling their promises in RA? H Schulz-Koops said a survey showed rheumatologists wanted effective fast acting Rx that could be used as monotherapy. @eular_org #EULAR2022 @RheumNow https://t.co/Gdel9YnAzA
Janet Pope Janetbirdope ( View Tweet)
More data on #iberdomide… from phase 2 study --looks like it helps #SCLE and #CCLE (but not for #ACLE) Dr. V Werth #EULAR2022 @rheumnow https://t.co/FYZlB219lf
TheDaoIndex KDAO2011 ( View Tweet)
Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb
TheDaoIndex KDAO2011 ( View Tweet)
#OP0252 #EULAR2022 Dr Yeoh presented data from Global Rheum Alliance of >300 pts with myositis. 13% died. Usual suspects re: Factors assoc with poor #COVID outcome: age, active disease,on steroid,male and RTX exposure. Be interesting to see longer followup post-booster @RheumNow https://t.co/F7qaee5ADK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/u9KkZrUKGo
Janet Pope Janetbirdope ( View Tweet)
#PEARLS by Dr. Werth:
1. anti-malarials only work 50% of time for cutaneous lupus (CLE).
2. AZP is not as effective as MTX or MMF for #CLE
3. Consider RTX refractory #bullous lupus #EULAR2022 @rheumnow https://t.co/6FPJEGWioJ
TheDaoIndex KDAO2011 ( View Tweet)
VIGIBASE registry RA
39000+ pts JAKi and 231000+ pts TNFi
*No increase in MACEs with JAKi 1.4% vs. 0.9%
*JAKi Increase in DVT RR 3.99
and PE RR 3.5
adjusted on age and sex
@RheumNow #OP0268 #EULAR2022 #Lupus https://t.co/hiAvKctgky
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2022
Rebuttal!
💻⚕️
Telemedicine improves patient-doctor relationship
Supplements F2F visits, making them more efficient
Patients are communicating, texting all the time
Can AI help improve early pt communication?
@ChristianDejaco
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Some / most of promises of #JAKi are fulfilled. Efficacy, adherence = on mono vs combination Rx with MTX. But some emerging safety issues. NK cells reduce inflammation of NK cells on fibroblasts re other MOA. @eular #EULAR2022 @RheumNow The promise of #JAKi I RA https://t.co/8Ry3vVMyzO
Janet Pope Janetbirdope ( View Tweet)
Gilbert et al. RA assoc increased risk hospitalisation or death from COVID-19 1.53 (1.20, 1.94). RA-ILD assoc even greater risk hospitalisation or death multivariable HR 2.84 [95% CI 1.64-4.91] @RheumNow #EULAR2022 OP0251 https://t.co/h1jzAV6xNR https://t.co/7E1EzAKCDv
Links:
Richard Conway RichardPAConway ( View Tweet)
Perrot et al. Factors assoc severe COVID in SpA. corticosteroid intake (3.15 [1.46-6.76]), age (OR=1.06 [1.04-1.08]) while anti-TNF (OR=0.26 [0.09-0.78]) was protective @RheumNow #EULAR2022 OP0254 https://t.co/bIiEW6efQ2
Links:
Richard Conway RichardPAConway ( View Tweet)
A new finding - antimalarials improve safety w bDMARDs & #JAKi and reduce CV events and improve drug survival #Bestinclass. POS0242 @RheumNow @eular_org #EULAR2022 Neat. Safe, inexpensive and monitor eyes 👀 https://t.co/Ea4VA9vqwe
Janet Pope Janetbirdope ( View Tweet)
Large 5 country cohort study - No increased risk of hematologic malignancies (lymphoid or myeloid) in PsA pts treated with TNFi.
In PsA overall compared to general population - moderately increased underlying risk of hematologic malignancies.
@RheumNow #EULAR2022 ABST#OP0257 https://t.co/P846RupitR
Robert B Chao, MD doctorRBC ( View Tweet)
#OP0783 #EULAR2022 A study in Spain (N=72) of #Sjogren pts showed Pathologic US of salivary glands were associated with Ro52+, raised IgG, early menopause & lack Mediterranean diet. Smoking was protective but wide Confidence Interval. I wont promote smoking though @RheumNow https://t.co/kn4X4oFGzK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Female PsA patients on TNFi have reduced treatment effectiveness, LDA (vs males). #EULAR2022 POS0077 @RheumNow https://t.co/EwDwxUarNb https://t.co/W5xgQlrnlF
Dr. Rachel Tate uptoTate ( View Tweet)
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
David Liew drdavidliew ( View Tweet)
#ClinicalPearl. Why do doctors prescribe #JAKi in RA? Efficacy, fast onset, X-ray inhibition, can work as monotherapy, remission - in order of diminishing frequency BUT I will add access and oral (convenience). POS0680 @RheumNow @eular_org #EULAR2022 https://t.co/XHtNqguqvh
Janet Pope Janetbirdope ( View Tweet)
#EULAR2022 Telemedicine: PROs
💻Triage, reduce wait time, direct other specialty referral
💻High agreement w F2F evaluation (79-97%)
💻Saves resources, react quickly to minor flare
💻Better adherence
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
BTKi are they effective in #rheumatology? Seem to work in preclinical models of inflammation but so far clinical results seem disappointing #POS0397 @RheumNow @eular_org #EULAR2022 https://t.co/2NjcMnU1d6
Janet Pope Janetbirdope ( View Tweet)